Results 201 to 210 of about 931,067 (298)

A Multidimensional Index Framework for Evaluating the Regulatory Applicability of ISO 10328 Using a Prosthetic Knee Case Study. [PDF]

Med Devices (Auckl)
Li J.
europepmc   +1 more source

Discovery of an Adaptive Neuroimmune Response Driving Itch and Fast Tick Removal with Implications for Preventing Pathogen Transmission

Advanced Science, EarlyView.
Itch‐induced tick removal (IITR): An acquired neuroimmune mechanism, itch‐induced tick removal, develops after repeated tick exposure, mobilizing T cells and macrophages at the tick bite site to trigger a rapid scratching response that facilitates timely tick removal within a critical window that precedes the transmission of many tick‐borne pathogens ...
Johannes S. P. Doehl, Tiago D. Serafim, Serena Doh, Charles S. Grugan, Eva Iniguez, Luana Rogerio, Ronja Frigard, Ranadhir Dey, Pedro Cecilio, Xinglong Gu, Pang‐Yen Tseng, Aline da Silva Moreira, Mahnaz Minai, James Oristian, Hans Ackerman, Steven Brooks, Caroline Percopo, Siu‐Ping Ng, Derron A. Alves, Lucas Tirloni, Jennifer M. Anderson, Adriana Marques, Fabiano Oliveira, Shaden Kamhawi, Daniel E. Sonenshine, José M. C. Ribeiro, Mark Hoon, Jesus G. Valenzuela   +27 more
wiley   +1 more source

The Impact of US Food and Drug Administration's Advisory and Enforcement Actions on US Sales of Esco Bars Products in 2023: Synthetic Control Approach.

JMIR Public Health Surveill
Shin H, Hannings J, Cahn Z, Xu X, Toblin R, Farrelly M, King BA.   +6 more
europepmc   +1 more source

Pivotal studies of pharmacotherapies approved by the US FDA for cancer treatment: a meta-analysis. [PDF]

Oncologist
Chow R, Im JHB, Zimmermann C, Richards GC, Heneghan C.   +4 more
europepmc   +1 more source

Delivery of Pleckstrin‐Homology Domains Suppresses PI3K/Akt Signaling and Breast Cancer Metastasis

Advanced Science, EarlyView.
Current therapies curb tumor growth but not metastasis. Obscurin, a giant metastasis suppressor lost in breast cancer, restrains PI3K/Akt signaling but is impractical to restore. We deploy a mini‐obscurin, comprising the obscurin‐PH‐domain, which sequesters PI3K‐p85, potently suppressing invasion and metastasis.
Matthew Eason, Anindya Sen, Suhan Cho, Se Jong Lee, Keyata Thompson, Md Musavvir Mahmud, Poornima Dubey, Talia Guardia, Anthony Kim, Stuart Martin, Nathan Wright, Konstantinos Konstantopoulos, Aikaterini Kontrogianni‐Konstantopoulos   +12 more
wiley   +1 more source

How would Marie Kondo design a protocol? In favor of subtractive change in clinical trials. [PDF]

Front Med (Lausanne)
Bender Ignacio R, Rowan K, Cook D.
europepmc   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

A Comparison of Regional Decisions for Doses and Administrations of New Drugs: Concordance, Discordance, and Dependencies. [PDF]

Clin Pharmacol Ther
Mita S, Ono S.
europepmc   +1 more source

Combating VEGFA‐siRNA‐Induced Metabolic Reprogramming via Glucose Utilization Deprivation

Advanced Science, EarlyView.
An ionizable lipid nanoparticle co‐delivers VEGFA siRNA and glucose oxidase to tumors to counteract VEGFA knockdown‐induced, glutamine‐driven metabolic compensation. Enzymatic glucose consumption reverses the adaptive pathways and restores metabolism toward baseline, thereby sensitizing tumors to therapy.
Lulu Zheng, Shuai Guo, Yingjixing Luo, Pengfei Wu, Haiyin Yang, Yingqiu Xie, Yuchuan Fan, Qing Liu, Bo Hu, Jia Huang, Yuanyu Huang   +10 more
wiley   +1 more source

Correction: Molecular resistance mechanisms to newly approved antibiotics (2017-2025) in WHO priority pathogens. [PDF]

Front Microbiol
Frontiers Production Office.
europepmc   +1 more source